[{"NetIncomeLoss_2_Q2_USD":-26124000.0,"PaidInKindInterest_2_Q2_USD":647000.0,"AccruedLiabilitiesCurrent_0_Q2_USD":5131000.0,"InventoryFinishedGoodsNetOfReserves_0_Q2_USD":1340000.0,"InterestPaidNet_2_Q2_USD":1299000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":840000.0,"RestrictedCashAndCashEquivalentsNoncurrent_0_Q2_USD":150000.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0_Q2_USD":4200000.0,"PaymentsForRestructuring_1_Q2_USD":264000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-42000.0,"Depreciation_2_Q2_USD":88000.0,"StockIssuedDuringPeriodValueNewIssues_2_Q2_USD":19990000.0,"IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets_2_Q2_USD":-4472000.0,"FinanceLeaseInterestPaymentOnLiability_2_Q2_USD":4000.0,"FinanceLeaseInterestPaymentOnLiability_1_Q2_USD":2000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":815000.0,"AssetsCurrent_0_Q2_USD":39832000.0,"OperatingLeaseExpense_1_Q2_USD":213000.0,"CommonStockSharesIssued_0_Q2_shares":125197899.0,"FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":28000.0,"FinanceLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":7000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":849000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_2_Q2_USD":-90000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q2_USD":-71000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"FinanceLeaseInterestExpense_1_Q2_USD":2000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q2_shares":15720098.0,"SellingAndMarketingExpense_1_Q2_USD":6089000.0,"SellingAndMarketingExpense_2_Q2_USD":14214000.0,"FinanceLeaseLiabilityNoncurrent_0_Q2_USD":26000.0,"RestructuringCharges_1_Q2_USD":590000.0,"OperatingLeaseExpense_2_Q2_USD":427000.0,"FinanceLeaseInterestExpense_2_Q2_USD":5000.0,"AccountsAndOtherReceivablesNetCurrent_0_Q2_USD":7350000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":124771000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":120151000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":8000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":62000.0,"GainsLossesOnExtinguishmentOfDebt_1_Q2_USD":0.0,"GainsLossesOnExtinguishmentOfDebt_2_Q2_USD":0.0,"FinanceLeasePrincipalPayments_1_Q2_USD":12000.0,"FinanceLeasePrincipalPayments_2_Q2_USD":20000.0,"CommonStockValue_0_Q2_USD":125000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_Q2_USD":0.0,"FiniteLivedIntangibleAssetsAccumulatedAmortization_0_Q2_USD":41883000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":4165000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":3276000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":8129000.0,"ClassOfWarrantOrRightOutstanding_0_Q2_shares":486812.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":436000.0,"ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_0_Q2_USD":1542000.0,"InventoryWorkInProcessNetOfReserves_0_Q2_USD":1058000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":22108000.0,"IncreaseDecreaseInInventories_2_Q2_USD":1635000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":4792000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":9152000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"OperatingLeaseLiability_0_Q2_USD":3149000.0,"FinanceLeaseLiability_0_Q2_USD":76000.0,"Liabilities_0_Q2_USD":65497000.0,"FinanceLeaseLiabilityPaymentsDue_0_Q2_USD":83000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":494633000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":22814000.0,"AmortizationOfIntangibleAssets_1_Q2_USD":615000.0,"AmortizationOfIntangibleAssets_2_Q2_USD":1230000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-12950000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-26124000.0,"FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q2_USD":55000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":2626000.0,"IncreaseDecreaseInContractWithCustomerLiability_2_Q2_USD":-15000.0,"Assets_0_Q2_USD":69685000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":2852000.0,"CommonStockSharesOutstanding_0_Q2_shares":125197899.0,"FinanceLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.125,"PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_Q2_USD":90000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2_Q2_USD":1895000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":735000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_Q2_USD":0.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q2_USD":0.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-21466000.0,"InventoryRawMaterialsNetOfReserves_0_Q2_USD":1375000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q2_USD":889000.0,"LiabilitiesCurrent_0_Q2_USD":9586000.0,"AccountsPayableCurrent_0_Q2_USD":3882000.0,"NonoperatingIncomeExpense_2_Q2_USD":-3528000.0,"NonoperatingIncomeExpense_1_Q2_USD":-1798000.0,"InterestExpense_2_Q2_USD":3590000.0,"InterestExpense_1_Q2_USD":1806000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":22964000.0,"NetIncomeLoss_1_Q2_USD":-12950000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":412000.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"OperatingLeasePayments_1_Q2_USD":215000.0,"OperatingLeasePayments_2_Q2_USD":430000.0,"FiniteLivedIntangibleAssetsNet_0_Q2_USD":26439000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":600000.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2_Q2_USD":187000.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.125,"FinanceLeaseRightOfUseAssetAmortization_1_Q2_USD":13000.0,"FinanceLeaseRightOfUseAssetAmortization_2_Q2_USD":27000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":164000.0,"LongTermDebtNoncurrent_0_Q2_USD":50259000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":5895000.0,"ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0_Q2_USD":1.23,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-491410000.0,"VariableLeaseCost_2_Q2_USD":18000.0,"VariableLeaseCost_1_Q2_USD":9000.0,"PreferredStockValue_0_Q2_USD":0.0,"FiniteLivedIntangibleAssetsGross_0_Q2_USD":68322000.0,"RestructuringReserve_0_Q2_USD":326000.0,"InventoryNet_0_Q2_USD":3773000.0,"OperatingIncomeLoss_1_Q2_USD":-11152000.0,"OperatingIncomeLoss_2_Q2_USD":-22596000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":69685000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":4122000.0,"CommonStockSharesAuthorized_0_Q2_shares":300000000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q2_USD":1176000.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":1016000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":19990000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":11611000.0,"ShareBasedCompensation_2_Q2_USD":1895000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":2709000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":1895000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":42000.0,"StockholdersEquity_0_Q2_USD":4188000.0,"OtherLiabilitiesCurrent_0_Q2_USD":573000.0,"FinanceLeaseLiabilityCurrent_0_Q2_USD":50000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":3026000.0,"ProfitLoss_2_Q2_USD":-26124000.0,"PreferredStockSharesAuthorized_0_Q2_shares":5000000.0,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.1,"IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2_Q2_USD":-2342000.0,"OperatingExpenses_1_Q2_USD":15274000.0,"OperatingExpenses_2_Q2_USD":34207000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":523000.0,"FinanceLeaseRightOfUseAsset_0_Q2_USD":74000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":735000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-0.22,"AccruedProfessionalFeesCurrent_0_Q2_USD":904000.0,"Ticker":"EYPT","CIK":"1314102","name":"EYEPOINT PHARMACEUTICALS, INC.","OfficialName":"EyePoint Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"2","uom":"USD","footnote":"nan","Market Cap":"408871503.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200805"}]